|
WO2021072259A1
|
|
Reduced volume formulations including amino acid entities
|
|
PE20210371A1
|
|
COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES AND THALASSEMIAS
|
|
US2019388377A1
|
|
Compositions and methods for the treatment of liver diseases and disorders
|
|
AU2019290662A1
|
|
Compositions for therapy and health containing amino acids with bitter taste
|
|
EP3810122A1
|
|
Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions
|
|
BR112020025831A2
|
|
manufacturing methods of amino acid compositions
|
|
EP3810276A1
|
|
Compositions and methods for the reduction or treatment of inflammation
|
|
WO2019246298A1
|
|
Compositions and methods for the reduction or treatment of fibrosis
|
|
US2020016104A1
|
|
Compositions and methods for the treatment of fat infiltration in muscle
|
|
PE20200747A1
|
|
AMINO ACID COMPOSITIONS FOR THE TREATMENT OF HEPATIC DISEASE
|
|
WO2019036442A1
|
|
Amino acid compositions for the treatment of neuronal injury
|
|
CN110678172A
|
|
Amino acid compositions for treating traumatic brain injury and methods of use thereof
|
|
KR20190099243A
|
|
Amino Acid Compositions and Methods for Treating Muscle Diseases and Disorders
|
|
CU20190058A7
|
|
AMINO ACID COMPOSITIONS RELATED TO IMPROVEMENTS IN LIVER FUNCTION
|
|
US2018125926A1
|
|
Compositions and Formulations and Methods of Production and Use Thereof
|
|
AU2013240271A1
|
|
Nutritive fragments, proteins and methods
|
|
EP3715365A1
|
|
Nutritive fragments, proteins and methods
|
